These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

591 related items for PubMed ID: 26098779

  • 1. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.
    Polo ML, Riggio M, May M, Rodríguez MJ, Perrone MC, Stallings-Mann M, Kaen D, Frost M, Goetz M, Boughey J, Lanari C, Radisky D, Novaro V.
    Oncotarget; 2015 Sep 08; 6(26):22081-97. PubMed ID: 26098779
    [Abstract] [Full Text] [Related]

  • 2. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X, Zhao M, Hao M, Sun X, Wang J, Mao Y, Zu L, Liu J, Shen Y, Wang J, Shen K.
    Mol Cancer Res; 2013 Oct 08; 11(10):1269-78. PubMed ID: 23814023
    [Abstract] [Full Text] [Related]

  • 3. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A, Inoue N, Yagi T, Nishimukai A, Miyagawa Y, Murase K, Imamura M, Enomoto Y, Takatsuka Y, Watanabe T, Hirota S, Sasa M, Katagiri T, Miyoshi Y.
    Clin Breast Cancer; 2015 Jun 08; 15(3):197-203. PubMed ID: 25600244
    [Abstract] [Full Text] [Related]

  • 4. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
    Abraham J.
    Expert Rev Anticancer Ther; 2015 Jan 08; 15(1):51-68. PubMed ID: 25306975
    [Abstract] [Full Text] [Related]

  • 5. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R.
    Breast Cancer Res; 2014 Sep 11; 16(5):430. PubMed ID: 25212826
    [Abstract] [Full Text] [Related]

  • 6. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
    Ciruelos Gil EM.
    Cancer Treat Rev; 2014 Aug 11; 40(7):862-71. PubMed ID: 24774538
    [Abstract] [Full Text] [Related]

  • 7. PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.
    Beelen K, Hoefnagel LD, Opdam M, Wesseling J, Sanders J, Vincent AD, van Diest PJ, Linn SC.
    Int J Cancer; 2014 Sep 01; 135(5):1257-63. PubMed ID: 24501006
    [Abstract] [Full Text] [Related]

  • 8. PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer.
    Riggio M, Polo ML, Blaustein M, Colman-Lerner A, Lüthy I, Lanari C, Novaro V.
    Carcinogenesis; 2012 Mar 01; 33(3):509-18. PubMed ID: 22180571
    [Abstract] [Full Text] [Related]

  • 9. PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation.
    Sharma VR, Gupta GK, Sharma AK, Batra N, Sharma DK, Joshi A, Sharma AK.
    Curr Pharm Des; 2017 Mar 01; 23(11):1633-1638. PubMed ID: 27848885
    [Abstract] [Full Text] [Related]

  • 10. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
    Wang T, Seah S, Loh X, Chan CW, Hartman M, Goh BC, Lee SC.
    Oncotarget; 2016 Jan 19; 7(3):2532-44. PubMed ID: 26565813
    [Abstract] [Full Text] [Related]

  • 11. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R, Pancholi S, Guest SK, Marangoni E, Gao Q, Thuleau A, Simigdala N, Polanska UM, Campbell H, Rani A, Liccardi G, Johnston S, Davies BR, Dowsett M, Martin LA.
    Mol Cancer Ther; 2015 Sep 19; 14(9):2035-48. PubMed ID: 26116361
    [Abstract] [Full Text] [Related]

  • 12. The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress.
    Bahrami A, Khazaei M, Shahidsales S, Hassanian SM, Hasanzadeh M, Maftouh M, Ferns GA, Avan A.
    J Cell Biochem; 2018 Jan 19; 119(1):213-222. PubMed ID: 28513879
    [Abstract] [Full Text] [Related]

  • 13. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.
    Grunt TW, Mariani GL.
    Curr Cancer Drug Targets; 2013 Feb 19; 13(2):188-204. PubMed ID: 23215720
    [Abstract] [Full Text] [Related]

  • 14. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Araki K, Miyoshi Y.
    Breast Cancer; 2018 Jul 19; 25(4):392-401. PubMed ID: 29086897
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F.
    Int J Cancer; 2013 Nov 19; 133(9):2089-101. PubMed ID: 23629727
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.
    Clin Cancer Res; 2004 Dec 01; 10(23):8059-67. PubMed ID: 15585641
    [Abstract] [Full Text] [Related]

  • 17. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
    Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW.
    Breast Cancer Res Treat; 2015 Jan 01; 149(1):69-79. PubMed ID: 25491778
    [Abstract] [Full Text] [Related]

  • 18. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
    Costa C, Pereira S, Lima L, Peixoto A, Fernandes E, Neves D, Neves M, Gaiteiro C, Tavares A, Gil da Costa RM, Cruz R, Amaro T, Oliveira PA, Ferreira JA, Santos LL.
    PLoS One; 2015 Jan 01; 10(11):e0141253. PubMed ID: 26569621
    [Abstract] [Full Text] [Related]

  • 19. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L, Chen J, Zhong XR, Luo T, Wang YP, Huang HF, Yin LJ, Qiu Y, Bu H, Lv Q, Zheng H.
    PLoS One; 2015 Jan 01; 10(3):e0120511. PubMed ID: 25816324
    [Abstract] [Full Text] [Related]

  • 20. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y, Li L, Huang M, Duan C, Zhang L, Chen J.
    Cell Signal; 2014 Dec 01; 26(12):2782-92. PubMed ID: 25193113
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.